---
title: "Ersodetug (RZ358) in Tumor hyperinsulinism: Natural history, survival, and mortality"
description: "Formulary evidence on Ersodetug (RZ358) in Tumor hyperinsulinism: Natural history, survival, and mortality. Topics: Insulinoma: survival by indolent or aggressive behavior across published series, Insulinoma: survival of non-metastatic and metastatic disease in a nationwide Finnish cohort, Insulinoma: causes of death and perioperative mortality in a nationwide Finnish cohort, Insulinoma: recurrence after curative-intent surgery, and 9 further topics. 13 evidence topics quoted from 10 sources."
canonical: "https://www.evicenter.com/drugs/ersodetug--tumor-hyperinsulinism/product-information-and-disease-description/natural-history-survival-and-mortality"
published: "2026-11-15T20:24:18-05:00"
modified: "2026-11-17T19:46:25-05:00"
---

# Ersodetug (RZ358) in Tumor hyperinsulinism: Natural history, survival, and mortality

<a id="heading-2.2.1.3"></a>

## 2.2.1.3 Natural History, Survival, and Mortality

<a id="topic-2.2.1.3-1"></a>

### Insulinoma: survival by indolent or aggressive behavior across published series

> “Approximately 10% to 15% of insulinomas belong to the aggressive category and 85% to 90% can be considered as indolent”
> “Patients with an aggressive insulinoma have lower survival compared with patients with an indolent insulinoma.”
> “The 5-year survival of patients with an indolent insulinoma has been reported to be 94% to 100% and for patients with an aggressive insulinoma this amounts to 24% to 67%”

Source: [Hofland et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10940262/)

<a id="topic-2.2.1.3-2"></a>

### Insulinoma: survival of non-metastatic and metastatic disease in a nationwide Finnish cohort

> “Overall survival was analysed with Kaplan–Meier and Cox regression analyses.”
> “During the follow-up, 25 (32%) patients and 63 (20%) controls deceased.”
> “In a Cox regression analysis, the median overall survival of 27.5 (95% CI: 24.1–30.8) years in the patients with a non-metastatic insulinoma did not significantly differ from the 33.2 (29.8–36.7) years in their controls (HR: 1.5 (0.9–2.6), P = 0.128).”
> “In the patients with a metastatic insulinoma, the survival was significantly impaired, with a median of 3.4 (2.9–4.0) years vs not reached in the controls (HR: 5.1 (1.9–13.3), P = 0.001).”
> “Three of the patients with metastatic insulinoma (33%), however, showed a remarkably long survival time of 6–30 years.”
> “In the multivariate analyses, older age and distant metastases were associated with decreased survival”

Source: [Peltola et al. (2021b)](https://pmc.ncbi.nlm.nih.gov/articles/PMC8784472/)

<a id="topic-2.2.1.3-3"></a>

### Insulinoma: causes of death and perioperative mortality in a nationwide Finnish cohort

> “Nine of the 25 insulinoma patients who deceased during the study period (36%) died due to an insulinoma-related cause: 6 patients died of metastatic insulinoma, 2 patients died of surgical complications, and 1 patient died due to complications of invasive diagnostics, as previously described”
> “With the two deaths due to surgical complications, the perioperative mortality, defined as any death occurring within 30 days after surgery, was 2.7%.”

Source: [Peltola et al. (2021b)](https://pmc.ncbi.nlm.nih.gov/articles/PMC8784472/)

<a id="topic-2.2.1.3-4"></a>

### Insulinoma: recurrence after curative-intent surgery

> “the 5-, 10-, and 15-years disease-free survival rates were 94, 93, and 90%, respectively.”

Source: [Peltola et al. (2021b)](https://pmc.ncbi.nlm.nih.gov/articles/PMC8784472/)

> “The risk of recurrence was greater among patients with MEN I (21% at 10 and 20 years) than in those without MEN I (5% at 10 years and 7% at 20 years).”

Source: [Service et al. (1991)](https://pubmed.ncbi.nlm.nih.gov/1677058/)

<a id="topic-2.2.1.3-5"></a>

### Insulinoma: long-term survival of a 60-year Mayo Clinic cohort

> “we found 224 patients in whom an initial pancreatic exploration at Mayo had confirmed the presence of insulinoma.”
> “For the total cohort, 7.6% had multiple endocrine neoplasia type I (MEN I), and 5.8% had malignant insulinoma.”
> “Although survival of the total cohort was not significantly impaired, it was significantly worse than expected for patients with malignant insulinoma (29% versus 88% expected at 10 years postoperatively).”

Source: [Service et al. (1991)](https://pubmed.ncbi.nlm.nih.gov/1677058/)

<a id="topic-2.2.1.3-6"></a>

### Insulinoma: survival of benign versus malignant disease at a single institution

> “A total of 311 patients were identified: 51 malignant and 260 benign.”
> “Overall survival at 5 years was 66.8% vs 95.4% for malignant and benign insulinoma respectively, p < 0.01.”

Source: [Sada et al. (2021)](https://pubmed.ncbi.nlm.nih.gov/32873371/)

<a id="topic-2.2.1.3-7"></a>

### Malignant insulinoma: population-based survival in the SEER registries

> “A total of 121 cases of malignant insulinoma were identified between 1973 and 2015.”
> “The median overall survival (OS) was 143 months, with 5-and 10-year OS observed in 58% and 55%, respectively”
> “5-year OS was 84% and 14% for the surgery and no-surgery groups, respectively, p < 0.001.”
> “On multivariable analysis, surgical resection, male sex, and absence of metastatic disease were associated with greater overall and cancer-specific survival”

Source: [Sada et al. (2020)](https://pmc.ncbi.nlm.nih.gov/articles/PMC7678752/)

<a id="topic-2.2.1.3-8"></a>

### Malignant insulinoma: survival and prognostic factors in an Italian multicenter series

> “Multicenter retrospective study on 31 patients (male: 61.3%) diagnosed between 1988 and 2017.”
> “The 5-year survival rate was 62%.”
> “Overall survival was significantly higher in patients with Ki-67 ≤10% (P = 0.03), insulin level <60 µU/mL (P = 0.015) and in patients who underwent surgery (P = 0.006).”

Source: [Veltroni et al. (2020)](https://pubmed.ncbi.nlm.nih.gov/32061159/)

<a id="topic-2.2.1.3-9"></a>

### Malignant insulinoma: onset of hypoglycemia after a non-functioning tumor

> “In 16.1% of the cases, the hypoglycaemic syndrome occurred after 46 ± 35 months from the diagnosis of originally non-functioning NET, whereas in 83.9% of the cases it led to the diagnosis of NET, of which 42.3% with a mean diagnostic delay of 32.7 ± 39.8 months.”

Source: [Veltroni et al. (2020)](https://pubmed.ncbi.nlm.nih.gov/32061159/)

<a id="topic-2.2.1.3-10"></a>

### Metastatic insulinoma: variable natural history in a National Institutes of Health series

> “The authors identified 10 patients with metastatic insulinoma.”
> “Second, four patients presented with metastatic disease to the liver, which appeared years after the initial diagnosis and presumed curative surgery.”
> “Finally, 9 of the 10 patients had a prolonged survival.”
> “The current study, as well as others, suggested that metastatic insulinoma may have a variable natural history.”

Source: [Hirshberg et al. (2005)](https://pmc.ncbi.nlm.nih.gov/articles/PMC4136659/)

<a id="topic-2.2.1.3-11"></a>

### Metastatic insulinoma: survival with multimodal treatment at a tertiary center

> “Clinical data on 14 patients with metastatic insulinoma (metastases to the liver, skeleton, and lung) were reviewed in this descriptive study.”
> “Seven subjects died during follow-up. The time of the 7 deaths ranged from 2.5 to 10.4 years (median time to death was 8.2 years).”
> “This compares to previous reports of median survival of about 2 years.”
> “Seven subjects are alive 1.2-12.3 years after diagnosis. Hypoglycemia was well-controlled and did not cause the deaths.”

Source: [Masharani et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11954510/)

<a id="topic-2.2.1.3-12"></a>

### NICTH: recovery and in-hospital mortality in a systematic review of published cases

> “Outcome data included tumour recurrence, hypoglycaemia and in‐hospital mortality.”
> “Outcomes were available for 223 cases, and the overall recovery rate among all the participants was 77% (n = 172).”
> “Most patients successfully recovered (77%); however, a significant mortality rate was identified (23%).”
> “Chronic liver disease (CLD) was more likely to be associated with death than recovery (OR: 7.23, P: 0.03).”
> “Fibrous tumours were significantly associated with recovery compared to non‐fibrous ones, and the association was statistically significant (65.1% vs. 33%, p < .001).”

Source: [Ata et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10897872/)

<a id="topic-2.2.1.3-13"></a>

### Tumor hyperinsulinism: company characterization of morbidity and mortality

> “Resulting hypoglycemia is often severe and may have serious adverse outcomes”
> “High morbidity and mortality rates”

Source: [Rezolute October corporate presentation (2026)](https://www.sec.gov/Archives/edgar/data/1509261/000110465926120205/tm2628517d1_ex99-1.htm)

## Related pages
- [Ersodetug (RZ358): Tumor hyperinsulinism](https://www.evicenter.com/drugs/ersodetug--tumor-hyperinsulinism) · [Markdown](https://www.evicenter.com/drugs/ersodetug--tumor-hyperinsulinism.md)
- [Ersodetug (RZ358) in Tumor hyperinsulinism: Terms and abbreviations](https://www.evicenter.com/drugs/ersodetug--tumor-hyperinsulinism/terms-and-abbreviations) · [Markdown](https://www.evicenter.com/drugs/ersodetug--tumor-hyperinsulinism/terms-and-abbreviations.md)
- [Ersodetug (RZ358): Tumor hyperinsulinism](https://www.evicenter.com/drugs/ersodetug--tumor-hyperinsulinism/executive-summary) · [Markdown](https://www.evicenter.com/drugs/ersodetug--tumor-hyperinsulinism/executive-summary.md)
- [Ersodetug (RZ358) in Tumor hyperinsulinism: Product information and disease description](https://www.evicenter.com/drugs/ersodetug--tumor-hyperinsulinism/product-information-and-disease-description) · [Markdown](https://www.evicenter.com/drugs/ersodetug--tumor-hyperinsulinism/product-information-and-disease-description.md)
- [Ersodetug (RZ358) in Tumor hyperinsulinism: Clinical evidence](https://www.evicenter.com/drugs/ersodetug--tumor-hyperinsulinism/clinical-evidence) · [Markdown](https://www.evicenter.com/drugs/ersodetug--tumor-hyperinsulinism/clinical-evidence.md)
- [Ersodetug (RZ358) in Tumor hyperinsulinism: Economic information and modeling report](https://www.evicenter.com/drugs/ersodetug--tumor-hyperinsulinism/economics) · [Markdown](https://www.evicenter.com/drugs/ersodetug--tumor-hyperinsulinism/economics.md)
- [Ersodetug (RZ358) in Tumor hyperinsulinism: References](https://www.evicenter.com/drugs/ersodetug--tumor-hyperinsulinism/references) · [Markdown](https://www.evicenter.com/drugs/ersodetug--tumor-hyperinsulinism/references.md)
